Search
Arformoterol
go.drugbank.com/drugs/DB01274ApprovedArformoterol is a bronchodilator. It works by relaxing muscles in the airways to improve breathing. … The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients
Mixtures: AIRBIR 3/100 MCG INHALASYON IÇIN TOZ IÇEREN KAPSÜL, 120 KPS, AIRBIR 3/100 MCG INHALASYON IÇIN TOZ IÇEREN KAPSÜL, 60 KPSCategories: Cytochrome P-450 Substrates, Adrenergic beta-2 Receptor AgonistsBelantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawnIn the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program. … [L44236] In July of 2025, belantamab mafodotin was approved by Health Canada for a similar indication, but for use in combination with either [Dexamethasone] and [Bortezomib] or [Dexamethasone] and [Pomalidomide
Categories: P-glycoprotein substratesNylidrin
go.drugbank.com/drugs/DB06152ApprovedWithdrawnNylidrin is a peripheral vasodilator. … FDA has considered nylidrin as "lacking substantial evidence of effectiveness" in cerebral ischemia, cerebral arteriosclerosis, and other cerebral circulatory insufficiencies.
Categories: 2-Amino-1-Phenylethanol Derivatives, Cytochrome P-450 SubstratesZilganersen
go.drugbank.com/drugs/DB18161ApprovedInvestigational[L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition … [L64096] Alexander disease is caused by variants in the *GFAP* gene that lead to overproduction and toxic accumulation of GFAP in astrocytes, and dysfunction in astrocytes can over time damage neurons
Alpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalIt works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival … To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests.
Categories: Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitors, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexmRNA-1345
go.drugbank.com/drugs/DB18739ApprovedInvestigationalmRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older. … mRNA-1345 is a nucleoside modified mRNA encoding the F-glycoprotein from RSV subtype A stabilized in its prefusion conformation.[L53393] It is the primary ingredient of the RSV vaccine mRESVIA.
Synonyms: Respiratory syncytial virus pre-fusion glycoprotein F mRNAExagamglogene autotemcel
go.drugbank.com/drugs/DB15572ApprovedInvestigational[L10139] Following engraftment, it causes an increase in the production of HbF and a subsequent decrease in HbS. … [L49231] It is the first CRISPR-based gene editing therapy to be approved in the United States.
Synonyms: gene editing consisting of a guide RNA (gRNA), Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediatedMedrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawnMedrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. … It was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigationalLunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … It is the first gene therapy to be approved under the Commissioner's National Priority Voucher (CNPV) pilot and represents one of the fastest BLA approvals in modern history, with a time between filing
Lebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigationalLebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate.[L51374] It binds to a different epitope compared [tralokinumab]. … This approval is based on the positive results obtained from the Phase 3 studies ADvocate 1 and ADvocate 2, where nearly 80% of patients taking lebrikizumab either as monotherapy or combination therapy